# SSBH 2025

## Symposium 1

Antiresorptives: What We've Learned and What Lies Ahead

# Michael R McClung

Founding Director Oregon Osteoporosis Center, USA

## Educational Background & Professional Experience

1987-Present Founding Director, Oregon Osteoporosis Center, Portland, OR, USA

1976–1987 Associate Professor, Oregon Health & Science University, Portland, OR, USA

1972–1976 Fellow, National Institutes of Health, Bethesda, MD, USA 1969–1972 Resident, Parkland memorial Hospital, Dallas, TX USA

#### Research Interests

Osteoporosis evaluation and management

### Publications

- 1. McClung MR. Sequential and long-term therapy for osteoporosis. Curr Osteoporos Rep. 2025
- 2. McClung MR, Betah D, Leder BZ, et al. Romosozumab improves microarchitecture as assessed by tissue thickness-adjusted trabecular bone score in postmenopausal women with osteoporosis. J Bone Miner Res. 2024
- 3. Reid IR, McClung MR. Osteopenia a key target for fracture prevention. Lancet Diabetes Endocrinol. 2024
- 4. Mäkinen VN, Sølling AS, McClung M, Langdahl BL. Romosozumab for the treatment of osteoporosis a systematic review. J Endocrinol Invest. 2024



11:10-11:35 | Room 1





